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SUMMARY
Telomere maintenance is critical for cancer progression. To examine mechanisms of tumor suppres-
sion induced by short telomeres, we crossed mice deficient for the RNA component of telomerase,
mTR/, with Em-myc transgenic mice, an establishedmodel of Burkitt’s lymphoma. Short telomeres
suppressed tumor formation in Em-myc transgenic animals. Expression of Bcl2 blocked apoptosis in
tumor cells, but surprisingly, mice with short telomeres were still resistant to tumor formation. Stain-
ing for markers of cellular senescence showed that pretumor cells induced senescence in response
to short telomeres. Loss of p53 abrogated the short telomere response. This study provides in vivo
evidence for the existence of a p53-mediated senescencemechanism in response to short telomeres
that suppresses tumorigenesis.INTRODUCTION
Burkitt’s lymphoma is a highly aggressive, rapidly grow-
ing, and lethal cancer. Tumors that arise are uniformly as-
sociated with translocations that activate the c-myc onco-
gene. A transgenic mouse model of Burkitt’s lymphoma in
which c-myc is expressed in B cells (Adams et al., 1985)
provides an excellent model to understand the biology
of lymphoma and to test mechanisms that may limit tumor
growth. Understanding the pathways that interrupt tumor
growth will allow the development of specific therapies for
lymphoma.
Cells contain two major intrinsic pathways of tumor sup-
pression, apoptosis and senescence, that can be acti-
vated by multiple stimuli (Lowe et al., 2004). Telomerase
inhibition was proposed as a potential cancer therapy
when telomere shortening was first described in human
cells (Harley et al., 1990). Telomerase is critical for telo-
mere length maintenance; when telomerase is absent or
blocked, progressive telomere shortening occurs witheach cell division. In primary cultures of human cells, telo-
mere shortening results in dysfunctional telomeres, which
trigger a DNA damage response that ultimately leads to an
irreversible state of cellular senescence (Bodnar et al.,
1998; d’Adda di Fagagna et al., 2003). In mouse cells,
short telomeres also initiate a DNA damage response (Hao
et al., 2004); however, in response, these cells do not enter
senescence (Blasco et al., 1997; Parrinello et al., 2003).
In vivo short telomeres induce apoptosis in multiple highly
proliferative tissues, including testis germ cells and lym-
phocytes (Hemann et al., 2001a; Lee et al., 1998). Senes-
cent cells were detected in a subset of hepatocytes that
were induced to proliferate via partial hepatectomy in
mice with dysfunctional telomeres (Lechel et al., 2005; Sa-
tyanarayana et al., 2003). However, senescence was not
observed in quiescent hepatocytes in animals with acute
telomere dysfunction due to telomere uncapping (Denchi
et al., 2006). Strong evidence has accumulated that short
telomeres indeed limit tumor growth. Crosses of mTR/
mice to tumor-prone models demonstrate that the shortSIGNIFICANCE
Telomerase inhibition has potential therapeutic benefits for cancer treatment. Experimental systems indicate that
short telomeres impair tumor formation by inducing apoptosis. Therefore, blocking apoptosis was expected to
block the tumor-suppressive effect of short telomeres. However, we found that, despite efficient inhibition of ap-
optosis, short telomeres retained potent tumor-suppressive signaling in Em-myc-induced lymphomas. This re-
sponse required p53 and showed hallmarks of cellular senescence. Thus, telomerase inhibition can engage mul-
tiple p53-dependent tumor suppressor pathways and may have therapeutic potential for tumors that have lost
specific p53 effector functions but retain wild-type p53.Cancer Cell 11, 461–469, May 2007 ª2007 Elsevier Inc. 461
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Short Telomere Senescence Suppresses TumorigenesisFigure 1. Short Telomeres Decrease Penetrance of Tumor Formation and Initiate Genomic Instability
(A) Kaplan-Meier survival analysis showing lymphoma onset inMyc;mTR+/+ (black, n = 31),Myc;mTR/G1 (blue, n = 18), andMyc;mTR/G5/6 (red,
n = 25) cohorts.
(B) Quantitative fluorescence in situ hybridization (Q-FISH) of tumor cell metaphase spreads from Myc;mTR+/+ (top), Myc;mTR/ G1 (middle), and
Myc;mTR/ G6 (bottom). Ten metaphases each from three separate lymphomas are represented for each genotype.
(C) Representative Q-FISH (top) and spectral karyotypes (SKY)(bottom) forMyc;mTR+/+ (left) andMyc;mTR/G6 (right) tumors. Arrowheads indicate
end-to-end chromosome fusions and nonreciprocal translocations in Q-FISH and SKY images, respectively.
(D) Quantitation of chromosome abnormalities. The number of chromosome end-to-end fusions (red bars) and nonreciprocal translocations (blue
bars) per metaphase are shown (ten metaphases per tumor, n = 3). Error bars indicate standard error.telomere response significantly limits tumor formation
(Gonzalez-Suarez et al., 2000; Greenberg et al., 1999; Qi
et al., 2003, 2005; Rudolph et al., 2001; Wong et al.,
2003). In these experiments, decreased tumor formation
correlated with an increase in DNA damage, chromosome
instability, and apoptosis. However, senescence was not
reported in these studies. Taken together, these observa-
tions raise the question whether short telomere-induced
senescence may act as a tumor suppressor mechanism.
The p53 tumor suppressor protein is the major mediator
of the DNA damage response, apoptosis, and senes-
cence. Consistent with this role, p53 deficiency abrogates
many of the cellular responses to short telomeres (Chin
et al., 1999). In addition, short telomeres stimulated the
formation of tumors in p53-deficient mice and caused
the occurrence of tumor types that are not normally asso-
ciated with this tumor-prone mouse model (Artandi et al.,
2000). The loss of p53 confers multiple advantages to un-
controlled proliferation, including loss of the DNA damage
checkpoint, genome stability, senescence, and apoptosis
(Vogelstein et al., 2000). It is therefore unclear which p53
effector functions are important for tumor suppression in
response to short telomeres.462 Cancer Cell 11, 461–469, May 2007 ª2007 Elsevier Inc.In the work presented here, we demonstrate that short
telomeres suppress tumorigenesis in a mouse model of
Burkitt’s lymphoma and examine the requirement of
apoptosis in mediating this response. We found that,
surprisingly, inhibition of apoptosis did not abrogate the
reduction in lymphoma formation in response to short
telomeres. After long latency, microlymphomas that did
appear displayed multiple markers of senescence. Ge-
netic evidence showed that p53 was absolutely required
for tumor suppression. We conclude that short telomeres
activate a p53-dependent cellular senescence pathway
that limits tumor formation in vivo.
RESULTS
The Em-myc transgenic mouse is an established model of
Burkitt’s lymphoma. Overexpression of theMyc oncogene
in B cells leads to B cell lymphoma with a median onset
of 4–6 months (Adams et al., 1985). To assess the impact
of short telomeres on lymphomagenesis, we generated
Em-myc transgenic mice that were deficient for the
RNA component of telomerase (Blasco et al., 1997)
(Em-myc;mTR/). To obtain Em-myc transgenic mice
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Short Telomere Senescence Suppresses Tumorigenesiswith short telomeres, we intercrossed Em-myc;mTR/
mice for six successive generations in the absence of
telomerase. This breeding strategy allows for the compar-
ison of Em-myc transgenic mice that are wild-type for
telomerase (Myc;mTR+/+), those that lack telomerase but
have long telomeres (Myc;mTR/ G1), and those that
lack telomerase but have short telomeres (Myc;mTR/
G5/6).
To determine the effect of short telomeres on tumor for-
mation, wemonitored cohorts ofMyc;mTR+/+,Myc;mTR/
G1, and Myc;mTR/ G5/6 mice for lymphoma onset.
Consistent with previous studies (Adams et al., 1985),
Myc;mTR+/+ and Myc;mTR/ G1 animals developed fully
penetrant B cell lymphoma, and the latency of lymphoma
onset was indistinguishable between the two cohorts (Fig-
ure 1A). In contrast, only 7 of 25Myc;mTR/G5/6 animals
developed lymphoma over the course of the study (p <
104, Figure 1A). As expected, telomere length was signif-
icantly shorter in Myc;mTR/ G5/6 tumors compared to
Myc;mTR+/+ and Myc;mTR/G1 tumors (Figure 1B). Fur-
ther, these tumors displayed a high frequency of chromo-
some end-to-end fusions and nonreciprocal transloca-
tions (Figures 1C and 1D). In contrast, Myc;mTR+/+ and
Myc;mTR/G1 tumors showed no nonreciprocal translo-
cations and only one independent, but clonal, end-to-end
chromosome fusion. These observations indicate that
short telomeres induce extensive genomic instability and
are a potent inhibitor of tumorigenesis in Em-myc trans-
genic mice.
Previous studies in telomerase-deficient mice have sug-
gested that the apoptotic pathway is critical for short telo-
mere tumor suppression (Gonzalez-Suarez et al., 2000;
Greenberg et al., 1999; Qi et al., 2003, 2005; Rudolph
et al., 2001; Wong et al., 2003). To directly test the require-
ment of apoptosis for short telomere-mediated tumor
suppression, we disabled apoptotic signaling by express-
ing the Bcl2 oncogene using an adoptive transfer protocol
(Figure 2A). We cultured bone marrow, enriched for
hematopoietic stem cells, from young, nonlymphomic
Myc;mTR+/+, Myc;mTR/ G1, and Myc;mTR/ G5/6 an-
imals. Whole bone marrow was infected with a murine
stem cell retrovirus (MSCV) that expresses Bcl2 and
EGFP from a bicistronic message (Schmitt et al., 2002).
Adoptive transfer of Bcl2 expressing Em-myc bone mar-
row into lethally irradiated syngeneic recipient animals re-
sults in rapid lymphoma onset approximately 6 weeks
posttransplant (Schmitt et al., 2002). Disabling apoptosis
results in a rapid onset of tumors during Em-myc lympho-
magenesis (Schmitt et al., 2002). As expected, transplan-
tation of Bcl2-positive HSCs derived from Myc;mTR+/+
andMyc;mTR/G1 animals resulted in rapid tumor onset
in all recipient animals in both genotypes (8 of 8
Bcl2;Myc;mTR+/+ and 7 of 7 Bcl2;Myc;mTR/ G1 mice
were lymphoma bearing by 42 days posttransplant
Figure 2B). These animals harbored highly aggressive tu-
mors displaying complete effacement of the cervical
lymph nodes and infiltration of tumor cells into adjacent
salivary gland. Surprisingly, animals transplanted with
Bcl2-positive Myc;mTR/ G5/6 bone marrow failed todevelop palpable tumors for more than 100 days post-
transplant (0 of 3 Myc;mTR/ G5 [129 days] and 0 of 5
Myc;mTR/ G6 [100 days]; Figure 2B). Histological eval-
uation of lymphatic tissues from these animals showed
small encapsulated tumor masses in the cervical lymph
nodes with little infiltration into salivary gland (Figure 5B).
To confirm that Bcl2 was blocking apoptosis in the tumor
cells in these animals, we used a terminal UTP nick end la-
beling (TUNEL) protocol to examine the extent of apopto-
sis in lymphomas from Bcl2-expressing mice. Apoptotic
levels were significantly reduced in Bcl2-expressing
Figure 2. Short Telomeres Suppress Lymphoma Formation
despite Abrogation of the Apoptotic Program
(A) Experimental bone marrow transplant scheme. Bone marrow from
donors of defined genotypes was infected with Bcl2-expressing mu-
rine stem cell virus prior to transplantation into lethally irradiated
wild-type recipient animals. Iconography reproduced by kind permis-
sion of New Science Press from Immunity (DeFranco et al., 2007).
(B) Kaplan-Meier survival analysis of Myc;mTR+/+ (black, n = 8),
Myc;mTR/ G1 (blue, n = 7), and Myc;mTR/ G5/6 (red, n = 3[G5],
n = 5 [G6]) cohorts.
(C) TUNEL analysis of tumor masses from Bcl2;Myc;mTR+/+,
Bcl2;Myc;mTR/ G5, and Bcl2;Myc;mTR/ G6. Error bars indicate
standard error.Cancer Cell 11, 461–469, May 2007 ª2007 Elsevier Inc. 463
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Short Telomere Senescence Suppresses TumorigenesisFigure 3. Short Telomeres Block Tumor Formation in a p53-Dependent Manner
(A) Intergenerational breeding scheme. Vertical bars represent telomere lengths.
(B) Kaplan-Meier survival analysis ofMyc;mTR+/;p53+/+ iG7 (black dashed line, n = 11),Myc;mTR/;p53+/+ iG7 (red dashed line, n = 20),Myc;mTR+/;
p53+/ iG7 (black solid line, n = 7), andMyc;mTR/;p53+/ iG7 (red solid line, n = 9) cohorts.Myc;p53+/animals invariably developMyc;p53/ tumors
at 40 days. Short telomeres promote chromosomal abnormalities in p53-deficient lymphomas.
(C) Q-FISH analysis of metaphase spreads from Myc;mTR+/;p53/ (top) andMyc;mTR/;p53/ (bottom) lymphomas. Ten metaphases each from
three separate lymphomas are represented for each genotype.
(D) Quantitation of chromosome abnormalities. The number of chromosome end-to-end fusions (red bars) and nonreciprocal translocations (blue bars)
per metaphase are shown (ten metaphases per tumor, n = 3). Error bars indicate standard error.lymphomas compared to spontaneously arising Em-myc
lymphomas that do not express Bcl2 (Figure 2C). Impor-
tantly, the amount of apoptotic cells was similar in all
Bcl2-positive lymphomas tested (Student’s t test; p =
0.6 for Myc;mTR+/+ to Myc;mTR/ G6 comparison).
These data indicate that short telomeres effectively abol-
ished tumor progression even when apoptosis was
blocked.
Decreased tumor formation in the absence of apoptosis
suggested that another mechanism is limiting tumor
growth. p53 regulates multiple pathways that act to
suppress tumor formation, including apoptosis and se-
nescence (Lowe et al., 2004; Vogelstein et al., 2000). To
genetically test whether p53 is required for the short
telomere-induced suppression of lymphoma, we crossed
mice doubly heterozygous for mTR and p53 (mTR+/;
p53+/) toMyc;mTR/G6 mice (Figure 3A). This cross re-
sults in intergenerational G7 (iG7) littermates that all have
half-long and half-short telomeres and are either telome-
rase positive (mTR+/) or telomerase negative (mTR/).464 Cancer Cell 11, 461–469, May 2007 ª2007 Elsevier Inc.The mTR/ iG7 mice have short telomeres that mimic
mTR/ G6 mice (Feldser et al., 2006; Hemann et al.,
2001b; Qi et al., 2003). Em-myc transgenic animals that
are heterozygous for p53 (p53+/) invariably develop
p53-deficient lymphomas due to loss of the remaining
wild-type p53 allele (LOH) (Schmitt et al., 1999). As
expected, Myc;mTR+/;p53+/ iG7 mice formed tumors
rapidly. Interestingly, Myc;mTR/;p53+/ iG7 mice also
formed tumors with similar rapid onset as their telome-
rase-positive counterparts; all animals developed lym-
phoma by day 42 after birth (Figure 3B). Despite similar
rates of lymphoma onset, mTR/ iG7 tumors had signif-
icantly shorter telomeres, high rates of chromosome
end-to-end fusions, and numerous nonreciprocal translo-
cations, whereas their telomerase-positive (mTR+/)
counterparts had none (Figure 3D). These genetic experi-
ments indicate that short telomere-induced tumor sup-
pression requires the p53 tumor suppressor pathway
and that loss of p53 abrogates the cellular response to
telomere dysfunction.
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Short Telomere Senescence Suppresses TumorigenesisFigure 4. Short Telomeres in Spontaneous Lymphomas from Em-Myc;mTR/ G5/6 Select for Mutations in p53
(A) Loss of apoptotic induction in tumor cells derived from Myc;mTR/ G5/6 mice. Six hours after 0 or 5 Gy g-IR treatment, cells were stained with
Annexin-V FLUOS (FL-1) and propidium iodide (FL-3) and processed by flow cytometry. Representative tumors from Myc;mTR+/+ (top) and
Myc;mTR/ G6 (bottom) are shown. Sensitivity to g-IR is shown by loss of viable cells (lower left quadrant) after irradiation.
(B) Summary of the percent of viable cells, as described in (A), for all tumors analyzed.
(C) Immunoblot of nonirradiated or irradiated (5 Gy g-IR) tumor cell lysates for p53, Arf, and Actin. Representative tumors from Myc;mTR+/+ (left panel)
and Myc;mTR/ G5/6 (right panel). Normal p53 induction is shown by comparing lanes 1 and 2, and 5 and 6, while overexpression of mutant p53 is
shown in lanes 3–4, 7–8, and 11–12. Complete loss of p53 protein is shown in lanes 9–10, and 13–14. Arf expression is seen only in samples with
suspected p53 mutations (Eischen et al., 1999).
(D) Radioresistant DNA synthesis in lymphomas with p53 mutations. Cells were treated with 5 Gy g-IR. After 1 hr, BrdU was added to culture medium,
then 6 hr postirradiation cells were fixed and stained with anti-BrdU antibody and subjected to FACS analysis (FL-3 = 7-AAD signal and FL-1 = anti-
BrdU FLUOS) (the boxed area indicates cells in S phase).In addition to these genetic data, several lines of evi-
dence suggest that loss of p53 is critical for tumor devel-
opment in the presence of short telomeres. First, tumors
that are derived from Myc;mTR/ G5/6 animals (Figure 1)
are unable to elicit a G1 checkpoint in response to g-IR,
and these tumors also do not initiate apoptosis after
g-IR treatment (Figures 4A, 4B, and 4D). Second, immu-
noblot analysis showed that, in these tumors, p53 was
either undetectable regardless of g-IR treatment or
grossly overexpressed and uninducible (Figure 4C).
Finally, p19ARF was overexpressed in all tumors from
Myc G5/6 animals (6 out of 6 lymphomas tested, c2 test
p = 0.01 compared to Myc;mTR+/+). These observations
are consistent with p53 inactivation in the tumors, either
by deletion or by point mutation, which impairs p53 degra-
dation (Eischen et al., 1999). This implies that, for tumors
to grow in the presence of short telomeres, the p53 path-
way must be inactivated.
The requirement for p53, but not apoptosis, implies that
p53-mediated cellular senescence may be responsible for
tumor suppression. To determine whether short telomerescould be blocking tumor progression by initiating senes-
cence, we analyzed microlymphomas from Bcl2;Myc;
mTR/ G5/6 animals (Figure 2) for proliferation defects
and the presence of senescence markers. We scored mi-
totic indices from tissue sections derived from Bcl2;Myc;
mTR+/+ and Bcl2;Myc;mTR/ G5/6 lymphomas. Com-
pared to Bcl2;Myc;mTR+/+ sections, Bcl2;Myc;mTR/
G5/6 sections had significantly fewer mitotic figures per
high-power field (Figure 5A; p < 0.0001), indicating that
short telomeres negatively affect cellular proliferation.
Next, Bcl2;Myc lymphomas were analyzed for the pres-
ence of markers that are specifically upregulated in senes-
cent tissues (Collado and Serrano, 2006).Bcl2-expressing
Myc;mTR/ G5/6 microlymphomas stained positive for
SA-bgal and displayed both p16INK4a and p15INK4b immu-
nohistochemical staining. In contrast, Bcl2-expressing
Myc;mTR+/+ lymphomas did not stain for any of these
markers (Figure 5B). These staining patterns indicate
that Bcl2-expressing Myc;mTR/G5/6 microlymphomas
were indeed senescent. Taken together with the failure of
these lymphomas to progress, these data indicate thatCancer Cell 11, 461–469, May 2007 ª2007 Elsevier Inc. 465
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Short Telomere Senescence Suppresses Tumorigenesisshort telomeres can induce senescence in vivo to effec-
tively abolish tumor progression.
DISCUSSION
Understanding cellular mechanisms that may limit tumor
growth could provide new therapeutic approaches to can-
cer therapy. Telomere shortening, through the inhibition of
telomerase, has been proposed as a potential cancer
treatment. Here we show that short telomeres can block
lymphoma induction in a mouse model of Burkitt’s lym-
phoma. Short telomeres have been shown to reduce tu-
Figure 5. Microlymphomas from Bcl2;Myc;mTR/ G5/6 Ani-
mals Are Senescent
(A) Mitotic indices for Bcl2;Myc;mTR+/+, Bcl2;Myc;mTR/ G5, and
Bcl2;Myc;mTR/ G6. Error bars indicate standard error.
(B) Histological analysis of Bcl2;Myc;mTR+/+ and Bcl2;Myc;mTR/
G6 lymphomas. Top: H&E stain showing complete effacement of cer-
vical lymph node in Bcl2;Myc;mTR+/+ and small encapsulated micro-
lymphoma surrounded by salivary glands in Bcl2;Myc;mTR/G6. Se-
nescence-associated b-gal activity and p16INK4a and p15INK4b
immunostain specifically associated with Bcl2;mTR/ G6 microlym-
phomas. Scale bar represents 250 mm for low-power H&E stained im-
ages (top panels) and 100 mm for all other images.466 Cancer Cell 11, 461–469, May 2007 ª2007 Elsevier Inc.mor formation in several other mouse tumor models (Gon-
zalez-Suarez et al., 2000; Greenberg et al., 1999; Qi et al.,
2003, 2005; Rudolph et al., 2001; Wong et al., 2003); how-
ever, in all of those systems, apoptosis was thought to
be responsible for the decreased incidence of tumor for-
mation. We found that blocking apoptosis still resulted in
tumor suppression. p53 was required for the tumor reduc-
tion due to short telomeres, and direct evidence indicated
that a p53-mediated senescence program was activated
in the small tumors that did form. These results indicate
that short telomeres can mediate a p53-dependent senes-
cence program that limits tumor formation in vivo.
Telomere-mediated senescence in tumors may not have
been detected in previous studies because it likely is
initiated in only a few cells. Recently, cellular senescence
induced by oncogene expression has been established
as a tumor suppressor mechanism in vivo (Braig et al.,
2005; Chen et al., 2005; Collado et al., 2005; Michaloglou
et al., 2005). Activation of cellular senescence in these
instances occurs in all cells in the initiating tumor mass,
thus facilitating detection of senescence markers. In con-
trast, senescence induced by short telomeres may occur
initially in only a few cells in which telomeres become
critically short. This may impede the detection of short-
telomere-mediated senescence during tumor formation.
Short telomeres can engage both the apoptosis and the
senescence pathways. p53 is necessary to carry out both
apoptotic and senescence pathways (Figure 6). The re-
quirement of the loss of p53 for the growth of the Em-myc
lymphomas with short telomeres suggests both apoptosis
and senescence play roles in limiting tumor growth. If only
one tumor suppressor pathway, apoptosis or senes-
cence, were necessary for short-telomere-mediated tu-
mor suppression, we would have expected mutations in
other components of these pathways to also allow tumor
formation in these mice. For example, if disruption of
apoptosis were the only p53 effector function required
for tumor formation in the presence of short telomeres,
we would have expected overexpression of Bcl2 to confer
a selective growth advantage regardless of telomere
length. Consistent with this, we speculate that loss of
p16 pathway components in tumors that express Bcl2
would be resistant to the tumor-suppressive effects of
short telomeres (Figure 6).Tumor suppressor programs in-
duced by p53 are context dependent. Restoration of p53
function in p53 null tumors induces tumor regression in
multiple tumor types (Martins et al., 2006; Ventura et al.,
2007; Xue et al., 2007). However, p53 restoration induces
apoptosis in lymphomas (Martins et al., 2006; Ventura
et al., 2007) and senescence in sarcomas (Ventura et al.,
2007) and liver carcinomas (Xue et al., 2007). It is unclear
whether p53-induced senescence or apoptosis correlates
with cell type, oncogenic lesion, or both. We show here
that, in a tumor type that is predisposed to p53-mediated
apoptosis, short telomeres can effectively redirect the
p53 tumor suppressor response to induce senescence. It
would be interesting if short telomeres could, likewise, alter
p53-mediated senescence programs to induce apoptosis
in tumor types predisposed to undergo senescence.
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effects on tumor formation. First, short telomeres promote
transformation of p53-deficient mouse embryo fibroblasts
(Chin et al., 1999). Second, short telomeres contribute to
mortality of tumor-prone p53 null mice by increasing tu-
mor formation and facilitating tumorigenesis in tissues not
usually prone to tumor formation in this system (Artandi
et al., 2000; Jacks et al., 1994). Here we used a mouse tu-
mor model in which the initiating mutation, the Myc trans-
gene, is unrelated to p53 and found that the growth of
tumors with short telomeres requires p53 loss. This
requirement for p53 has implications for the clinical appli-
cation of telomerase inhibitors. First, the fact that short
telomeres can induce both apoptosis and senescence to
limit tumorigenesis indicates that both of these pathways
can be targeted in cancer therapy. However, the data also
imply that telomerase inhibition will be most effective in tu-
mors that have an intact p53 pathway. Alternatively, telo-
merase inhibition may be combined with approaches that
reinstate p53 function or other mechanisms to activate se-
nescence or apoptosis programs in tumors. The lym-
phoma model described here thus provides an excellent
system to understand the genetic requirements that will
guide the development of more sophisticated approaches
to targeting telomerase in cancer therapy.
EXPERIMENTAL PROCEDURES
Lymphoma Monitoring and Analysis
The Institutional Animal Care and Use Committee at the Johns Hopkins
University approved all animal procedures.Em-myc transgenic animals
Figure 6. Tumor Suppressor Signaling Downstream of Short
Telomeres and Myc
The myc oncogene negatively regulates its effects on cell proliferation
by inducing both Arf and Bim tumor suppressors. Arf activity results in
stabilization of the p53 protein, whereas Bim is directly transcribed by
myc and induces apoptosis by inhibiting Bcl2. Activation of both Arf
and Bim is required for myc-induced apoptosis. Apoptotic signaling
can also be disrupted by overexpression of the downstream antiapop-
totic Bcl2 oncogene. The short telomere response signals through
both p16 and p53 tumor suppressor pathways, which carry out senes-
cence and/or apoptotic tumor suppressor functions. The p53 tumor
suppressor lies at the crossroads of senescence and apoptosis and
is required for both programs.were inspected twice weekly for lymph node enlargement by palpation
and for overall signs of distress. Animals were considered lymphomic
when tumor mass was easily palpated no more than 1 cm in diameter.
Lymphoma-bearing animals were euthanized, and tumor masses were
dissociated through nylon mesh into single-cell suspensions and cul-
tured on mitomycin C-treated 3T3 feeder layers in B cell media (45%
DMEM [Invitrogen], 45% IMDM [Invitrogen], 10% FBS [Hyclone],
Pen/Strep/Glutamine [Invitrogen]).
Chromosome Analysis
Metaphase spreads were generated by arresting exponentially grow-
ing cultures with 0.5 mg/ml KaryoMax (Gibco) 2 hr before hypotonic
swelling in 0.075 M KCl and fixation in 3:1 methanol:acetic acid. Fixed
cells were dropped onto glass slides over a steaming water bath. Telo-
mere length was determined by hybridization of metaphases with Cy3
(CCCTAA)3 PNA probes (PE Biosystems) as described (Lansdorp
et al., 1996). Spectral karyotyping was performed on metaphases
as described (Liyanage et al., 1996). Images were obtained using
IP-Lab software on a Zeiss Axioscope microscope.
Immunoblot, Apoptosis, and Cell-Cycle Analysis
Exponentially growing lymphoma cells (2 3 106) were grown in 6-well
plates. Cells were exposed to 0 or 5 Gy g-IR from a cesium source
(Gamma Cell) prior to analyses. For immunoblot analysis, cells were
lysed in RIPA buffer containing protease inhibitors (Roche), denatured
in SDS loading buffer, separated on a 4%–12% gradient Tris-acetate
gel (Novex), transferred to PVDF (MilliPore), and probed with anti-
p53 (CM5 Novocastra), anti-Arf (Ab80 Abcam), and anti-actin (Sigma).
For apoptosis analysis, cells were harvested, washed in PBS, and then
stained with an Annexin-V FLUOS staining kit (Roche) per the manu-
facturer’s instructions. For BrdU incorporation, BrdU was added to
culture medium 1 hr postirradiation, and analysis was performed 6 hr
after g-IR. Cells were harvested and analyzed using an in situ cell pro-
liferation kit (Roche) per the manufacturer’s instructions.
Bone Marrow Transplantation Protocol
and Retrovirus Production
Donor animals (6- to 10-week-old on C57BL/6J background) were
primed with 5-FU (150 mg/kg) 4 days prior to bone marrow harvest.
Marrow was harvested from tibia and femur by flushing with Hank’s
balanced salt solution with a 23-gauge needle. After red cell lysis, cells
were cultured in IMDM with 18% FBS (Hyclone) 4% WEHI-3 condi-
tioned media, 10 ng/ml IL-3, 10 ng/ml IL-6, and 100 ng/ml mSCF (Fitz-
gerald). Ecotropic retrovirus was produced using Phoenix cells (G. No-
lan, Stanford) by transfecting 12 mg MSCV:Bcl2 (Schmitt et al., 2002)
into 23 106 cells with 20 ml Lipofectamine 2000 (Invitrogen) overnight.
Virus was collected 24 and 48 hr posttransfection and used immedi-
ately to infect bone marrow cells four times by 90 min spinfection
(1000 g). Recipient animals (C57BL/6J, Jackson Labs) were lethally
irradiated with 9 Gy total body g-IR (Gamma Cell cesium source)
and transplanted with 2.5 3 105 bone marrow cells.
In Situ Apoptosis and Mitosis
Formalin-fixed tissue sections were stained using an in situ cell death
kit (Roche) per the manufacturer’s instructions and counterstained
with DAPI. Mitotic cells were counted based on morphology, and ap-
optotic cells were identified by Cy-3 label after TUNEL reaction.
Histology and Immunohistochemistry
Tissues harvested from lymphoma-bearing animals were fixed in 4%
neutral buffered formalin and then sectioned into 5 mm thick sections
for H&E and immunochemical stain. Prior to antibody hybridization, an-
tigens were retrieved by boiling slides for 10 min in 10 mM citrate so-
lution. Positive staining was routinely assessed by comparing serial
sections exposed to either specific primary antibodies or antibody di-
lution buffer only (negative controls). All subsequent steps were iden-
tical. p16Ink4a antibody (F-12 Santa Cruz; 1:100) and p15INK4b antibody
(Ab-6 Lab Vision; 1:50) were visualized with a Vectastain Elite kitCancer Cell 11, 461–469, May 2007 ª2007 Elsevier Inc. 467
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Short Telomere Senescence Suppresses Tumorigenesis(Vector Labs). For SAb-gal activity, tissues were snap frozen in OCT
mounting media (Sakura), and 12 mm sections were stained as de-
scribed (Dimri et al., 1995).
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